SPEAKERS

Alexandros Patsilinakos

Head of Medicinal Chemistry

Sibylla Biotech srl

Andreas Mantoulidis

Head of Medicinal Chemistry Lab

Boehringer Ingelheim

Andrew Potterton

Chief Technology Officer

Ternary Therapeutics

Andy Pike

Project leader, DMPK, Oncology R&D

AstraZeneca

Arnout Schepers

CEO

TenAces Biosciences

Benedict Cross

Chief Technology Officer

PhoreMost

Chinatsu Sakata-Sakurai

Vice President - Primary Focus Targeted Protein Degradation Lead

Astellas Pharma

Chris Tame

Chief Executive Officer

Ternary Therapeutics

Gali Prag

PI and SCF

Coltac Therapeutics

Giovanni Spagnolli

Chief Technology Officer

Sibylla Biotech srl

Heide Duevel

PROTAC Technology Platform Lead

Merck Healthcare KGaA

Ian Storer

Head of Hit Discovery

AstraZeneca

Kevin Wilson

Vice President & Head of Chemistry

Foghorn Therapeutics

Koichi Ito

Senior Director, Biology

Prelude Therapeutics​

Kurt Pike

Senior Director, External Innovation

Johnson & Johnson

Luc Brunsveld

Professor

Technical University of Eindhoven

Luca Naef

Co-Founder & Chief Technology Officer

VantAI

Markus Queisser

Scientific Director

GSK

Matthias Brand

Chief Scientific Officer

Proxygen

Maureen Galmes-Spit

Vice President - Research

Laigo Bio

Randolph Lopez

Chief Technological Officer

A-Alpha Bio

Rick Ewing

Vice President & Head of Chemistry

Rapafusyn Pharmaceuticals

Simon Glerup

Chief Scientific Officer

Draupnir Bio Aps

Vivek Vishnudas

Chief Technology Officer

BPG Bio

William Mcewan

Fellow

Cancer Research UK

Zhangping Xiao

Marie Curie Fellow Postdoc, Tate Group

Imperial College London

Zoran Rankovic

Director & Professor - Chemical Biology & Protein Degradation

Institute of Cancer Research

REGISTER
PARTNER